Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder

Biological Psychiatry

Volumn 46, Issue 9, 1999, Pages 1234-1242

  Biederman, Joseph ^a   Spencer, Thomas ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ADHD; Noradrenergic; Psychiatry

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ATOMOXETINE; CATECHOLAMINE; CLONIDINE; DESIPRAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; GUANFACINE; IMIPRAMINE; NORTRIPTYLINE; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

AROUSAL; ATTENTION; ATTENTION DEFICIT DISORDER; CATECHOLAMINE UPTAKE; COGNITION; DOPAMINERGIC SYSTEM; FAMILY STUDY; HEREDITY; HUMAN; MOLECULAR GENETICS; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEGREGATION ANALYSIS; SUDDEN DEATH; TWINS;

AROUSAL; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NOREPINEPHRINE; PSYCHOTROPIC DRUGS;

EID: 0033232482     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00192-4     Document Type: Review

References (90)

1. Abramowicz M (1991): Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 32:53.
2. Adler L, Resnick S, Kunz M, Devinsky O (1995): Open-label trial of venlafaxine in attention deficit disorder. New Clinical Drug Evaluation Unit Program, Orlando.
3. Arnsten A. Development of the cerebral cortex XIV. Stress impairs prefrontal cortical function . J Am Acad Child Adolesc Psychiatry. 38:1999;220-222.
4. Arnsten A., Steere J., Hunt R. The contribution of a-2 noradrenergic mechanisms to prefrontal cortical cognitive function Potential significance to attention deficit hyperactivity disorder . Arch Gen Psychiatry. 53:1996;448-455.
5. Bailey J.N., Palmer C.G.S., Ramsey C., Cantwell D., Kim K., Woodward J.A., et al. DRD4 gene and susceptibility to attention deficit hyperactivity disorder Differences in familial and sporadic cases . Am J Med Genet. 74:1997;623.
6. Barkley R. ADHD and the Nature of Self-Control. 1997;Guilford, New York.
7. Barrickman L., Noyes R., Kuperman S., Schumacher E., Verda M. Treatment of ADHD with fluoxetine A preliminary trial . J Am Acad Child Adolesc Psychiatry. 30:1991;762-767.
8. Barrickman L., Perry P., Allen A., Kuperman S., Arndt S., Herrmann K., et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 34:1995;649-657.
9. Benjamin J, Patterson C, Greenberg BD, Murphy DL, Hamer DH (1996, January 12): Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nature Genet 81-84.
10. Biederman J., Baldessarini R., Goldblatt A., Lapey K., Doyle A., Hesslein P. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic finding in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry. 32:1993;805-813.
11. Biederman J., Baldessarini R.J., Wright V., Keenan K., Faraone S. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder III. Lack of impact of comorbidity and family history factors on clinical response . J Am Acad Child Adolesc Psychiatry. 32:1993;199-204.
12. Biederman J., Baldessarini R.J., Wright V., Knee D., Harmatz J. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder I. Efficacy . J Am Acad Child Adolesc Psychiatry. 28:1989;777-784.
13. Biederman J., Gastfriend D.R., Jellinek M.S. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol. 6:1986;359-363.
14. Biederman J., Thisted R., Greenhill L., Ryan N. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry. 56:1995;87-93.
15. Cantwell D.P. Genetics of hyperactivity. J Child Psychol Psychiatry. 16:1975;261-264.
16. Casat C.D., Pleasants D.Z., Schroeder D.H., Parler D.W. Bupropion in children with attention deficit disorder. Psychopharmacol Bull. 25:1989;198-201.
17. Casat C.D., Pleasants D.Z., Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull. 23:1987;120-122.
18. Castellanos F.X., Lau E., Tayebi N., Lee P., Long R.E., Giedd J.N., et al. Evidence that a D4DR*7R dopamine receptor polymorphism is not correlated with attention deficit/hyperactivity disorder. Am J Med Genet. 74:1997;623.
19. Chappell P., Riddle M., Scahill L., Lynch K., Schultz R., Arnsten A., et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette=s syndrome. J Am Acad Child Adolesc Psychiatry. 34:1995;1140-1146.
20. Comings D.E., Comings B.G., Muhleman D., Dietz G., Shahbahrami B., Tast D., et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA. 266:1991;1793-1800.
21. Conners C., Casat C., Gualtieri C., Weller E., Reader M., Reiss A., et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 35:1996;1314-1321.
22. Cook E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., et al. Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet. 56:1995;993-998.
23. Cox W. An indication for the use of imipramine in attention deficit disorder. Am J Psychiatry. 139:1982;1059-1060.
24. Dillon D.C., Salzman I.J., Schulsinger D.A. The use of imipramine in Tourette's syndrome and attention deficit disorder Case report . J Clin Psychiatry. 46:1985;348-349.
25. Ebstein R.P., Novick O., Umansky R., Priel B., Osher Y., Blaine D., et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nature Genet. 12:1996;78-80.
26. Faraone S., Biederman J. Genetics of attention-deficit hyperactivity disorder. Child Adolesc Psychiatric Clin North Am. 3:1994;285-302.
27. Faraone S., Biederman J. Is attention deficit hyperactivity disorder familial? Harvard Rev Psychiatry. 1:1994;271-287.
28. Faraone S.V., Biederman J. Neurobiology of attention deficit hyperactivity disorder. Biol Psychiatry. 44:1998;951-958.
29. Faraone S.V., Biederman J., Weiffenbach B., Keith T., Chu M.P., Weaver A., et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry. 456:1999;768-770.
30. Findling R., Schwartz M., Flannery D., Manos M. Venlafaxine in adults with ADHD An open trial . J Clin Psychiatry. 57:1996;184-189.
31. Garfinkel B.D., Wender P.H., Sloman L., O'Neill I. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry. 22:1983;343-348.
32. Gastfriend D.R., Biederman J., Jellinek M.S. Desipramine in the treatment of attention deficit disorder in adolescents. Psychopharmacol Bull. 21:1985;144-145.
33. Gill M., Daly G., Heron S., Hawi Z., Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry. 2:1997;311-313.
34. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
35. Gittelman-Klein R. Pilot clinical trial of imipramine in hyperkinetic children. Conners C. Clinical Use of Stimulant Drugs in Children. 1974;192-201 Excerpta Medica, The Hague, Netherlands.
36. Greenberg L., Yellin A., Spring C., Metcalf M. Clinical effects of imipramine and methylphenidate in hyperactive children. Int J Ment Health. 4:1975;144-156.
37. Gross M. Imipramine in the treatment of minimal brain dysfunction in children. Psychosomatics. 14:1973;283-285.
38. Gualtieri C.T., Evans R.W. Motor performance in hyperactive children treated with imipramine. Percept Motor Skills. 66:1988;763-769.
39. Gunning B (1992): A controlled trial of clonidine in hyperkinetic children. Thesis. Department of Child and Adolescent Psychiatry, Academic Hospital Rotterdam-Sophia Children's Hospital Rotterdam, The Netherlands.
40. Hauser P., Zametkin A., Martinez P., Vitiello B., Matochik J., Mixson A., et al. Attention deficit-hyperactivity disorder in people with generalized resistance to thyroid hormone. N Engl J Med. 328:1993;997-1001.
41. Hoge S.K., Biederman J. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry. 47:1986;478-479.
42. Hornig-Rohan M, Amsterdam J (1995): Venlafaxine versus stimulant therapy in patients with dual diagnoses of ADHD and depression. New Clinical Drug Evaluation Unit Program, Orlando, Fla.
43. Horrigan J.P., Barnhill L.J. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol. 5:1995;215-223.
44. Huessy H., Wright A. The use of imipramine in children's behavior disorders. Acta Paedopsychiatrie. 37:1970;194-199.
45. Hunt R., Arnsten A., Asbell M. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 34:1995;50-54.
46. Hunt R.D. Treatment effects of oral and transdermal clonidine in relation to methylphenidate An open pilot study in ADD-H . Psychopharmacol Bull. 23:1987;111-114.
47. Hunt R.D., Minderaa R.B., Cohen D.J. Clonidine benefits children with attention deficit disorder and hyperactivity Report of a double-blind placebo-crossover therapeutic trial . J Am Acad Child Psychiatry. 24:1985;617-629.
48. Jakala P., Riekkinen M., Sirvio J., Koivisto E., Kejonen K., Vanhenaen M., et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 20:1999;460-470.
49. Kennedy JL, Richter P, Swanson JM, Wigal SB, LaHoste GJ, Sunohara G (1997): Association of dopamine D4 receptor gene and ADHD. Annual Meeting of the American Psychiatric Association, San Diego, CA.
50. Kornetsky C. The psychopharmacology of the immature organism. Psychopharmacologia. 17:1970;105-136.
51. Kupietz S.S., Balka E.B. Alterations in the vigilance performance of children receiving amitriptyline and methylphenidate pharmacotherapy. Psychopharmacology. 50:1976;29-33.
52. LaHoste G.J., Swanson J.M., Wigal S.B., Glabe C., Wigal T., King N., et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1:1996;128-131.
53. Lanau F., Zenner M., Civelli O., Hartman D. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. J Neurochem. 68:1997;804-812.
54. Luh J, Pliszka S, Olvera R, Tatum R (1995): An open trial of venlafaxine in the treatment of ADHD. Scientific proceedings of the American Academy of Child and Adolescent Psychiatry, New Orleans.
55. Malhotra A.K., Virkkunen M., Rooney W., Eggert M., Linnoila M., Goldman D. The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat polymorphism and novelty seeking. Mol Psychiatry. 1:1996;388-391.
56. Mattes J.A. The role of frontal lobe dysfunction in childhood hyperkinesis. Comp Psychiatry. 21:1980;358-369.
57. Morrison J.R., Stewart M.A. The psychiatric status of the legal families of adopted hyperactive children. Arch Gen Psychiatry. 28:1973;888-891.
58. NIMH (1996): Alternative Pharmacology of ADHD, Conference Proceedings February 1996, Washington, DC.
59. Pliszka S., McCracken J., Maas J. Catecholamines in attention-deficit hyperactivity disorder Current perspectives . J Am Acad Child Adolesc Psychiatry. 35:1996;264-272.
60. Prince J, Wilens T, Biederman J, Spencer T, Millstein R, Polisner D, Bostic J (1999): A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. Scientific Proceedings of the Annual Meeting: American Academy of Child and Adolescent Psychiatry, Chicago. Washington, DC: The American Academy of Child and Adolescent Psychiatry.
61. Quinn P.O., Rapoport J.L. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry. 132:1975;241-245.
62. Rapoport J.L., Quinn P., Bradbard G., Riddle D., Brooks E. Imipramine and methylphenidate treatment of hyperactive boys A double-blind comparison . Arch Gen Psychiatry. 30:1974;789-793.
63. Rapport M., Carlson G., Kelly K., Pataki C. Methylphenidate and desipramine in hospitalized children I. Separate and combined effects on cognitive function . J Am Acad Child Adolesc Psychiatry. 32:1993;333-342.
64. Reimherr F, Hedges D, Strong R, Wender P (1995): An open-trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. New Clinical Drug Evaluation Unit Program, Orlando.
65. Riddle M.A., Hardin M.T., Cho S.C., Woolston J.L., Leckman J.F. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics Preliminary clinical experience . J Am Acad Child Adolesc Psychiatry. 27:1988;811-814.
66. Satterfield J.H., Dawson M.E. Electrodermal correlates of hyperactivity in children. Psychophysiology. 8:1971;191-197.
67. Singer S., Brown J., Quaskey S., Rosenberg L., Mellits E., Denckla M. The treatment of attention-deficit hyperactivity disorder in Tourette=s syndrome A double-blind placebo-controlled study with clonidine and desipramine . Pediatrics. 95:1994;74-81.
68. Solanto M. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder a review and integration . Behav Brain Res. 94:1998;127-152.
69. Spencer T (1997): A double-blind, controlled study of desipramine in children with ADHD and tic disorders. Scientific Proceedings of the Annual Meeting: American Academy of Child and Adolescent Psychiatry, Toronto.
70. Spencer T., Biederman J., Kerman K., Steingard R., Wilens T. Desipramine in the treatment of children with tic disorder or Tourette's Syndrome and attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 32:1993;354-360.
71. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 155:1998;693-695.
72. Spencer T, Biederman J, Wilens T, Prince J, Rea J (1999): An open, dose ranging study of tomoxetine in children with ADHD. Scientific proceedings of International Society for Research in Child and Adolescent Psychopathology. Barcelona.
73. Spencer T., Biederman J., Wilens T., Steingard R., Geist D. Nortriptyline in the treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 32:1993;205-210.
74. Steingard R., Biederman J., Spencer T., Wilens T., Gonzalez A. Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 32:1993;350-353.
75. Sunohara G, Barr C, Jain U, Schachar R, Roberts W, Tannock R, et al (1997): Association of the D4 receptor gene in individuals with ADHD. American Society of Human Genetics, Baltimore.
76. Swanson J.M., Sunohara G.A., Kennedy J.L., Regino R., Fineberg E., Wigal T., et al. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD) A family-based approach . Mol Psychiatry. 3:1998;38-41.
77. Tatsumi M., Groshan K., Bakely R., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 340:1997;249-258.
78. Trott G.E., Friese H.J., Menzel M., Nissen G. [Use of moclobemide in children with attention deficit hyperactivity disorder] Wirksamkeit und vertraglichkeit des selektiven MAO-A-Inhibitors moclobemid bei kindern mit hyperkinetischem syndrom (both English and German versions). Z Kinder Jugendpsychiatr. 19:1991;248-253.
79. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, et al (1996): Association of the dopamine transporter gene (DAT1) and attention deficit hyperactivity disorder in children. Am J Hum Genet 63:1767-1776.
80. Watter N., Dreyfuss F.E. Modifications of hyperkinetic behavior by nortriptyline. Va Med Monthly. 100:1973;123-126.
81. Wender P.H., Reimherr F.W. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 147:1990;1018-1020.
82. Werry J. Imipramine and methylphenidate in hyperactive children. J Child Psychol Psychiatry. 21:1980;27-35.
83. Wilens T., Biederman J., Abrantes A., Spencer T. A naturalistic assessment of protriptyline for attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 35:1996;1485-1490.
84. Wilens T.E., Biederman J., Geist D.E., Steingard R., Spencer T. Nortriptyline in the treatment of attention deficit hyperactivity disorder A chart review of 58 cases . J Am Acad Child Adolesc Psychiatry. 32:1993;343-349.
85. Wilens T.E., Biederman J., Prince J., Spencer T.J., Faraone S.V., Warburton R., et al. Six-week, double blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 153:1996;1147-1153.
86. Wilens T.E., Biederman J.B., Mick E., Spencer T. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis. 183:1995;48-50.
87. Wilens TE, Spencer T (1999): Combining methylphenidate and clonidine: A clinically sound medication option. J Am Child Adolesc Psychiatry 38:614-622.
88. Winsberg B.G., Bialer I., Kupietz S., Tobias J. Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. Am J Psychiatry. 128:1972;1425-1431.
89. Yepes L.E., Balka E.B., Winsberg B.G., Bialer I. Amitriptyline and methylphenidate treatment of behaviorally disordered children. J Child Psychol Psychiatry. 18:1977;39-52.
90. Zametkin A.J., Rapoport J.L. Noradrenergic hypothesis of attention deficit disorder with hyperactivity A critical review . Meltzer H.Y. Psychopharmacology The Third Generation of Progress . 1987;837-842 Raven Press, New York.